Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
Authors:
Open Access
- 2 February 2022
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 7 (4) , 699-707
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 20 references indexed in Scilit:
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysisThe Lancet Diabetes & Endocrinology, 2019
- Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions—Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) ProgramDiabetes, 2018
- Globalization of Heart Failure Clinical Trials: A Systematic Review of 305 Trials Conducted Over 16 YearsEuropean Journal of Heart Failure, 2018
- Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-AnalysisDiabetes Therapy, 2017
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysisDiabetologia, 2013
- Diabetes in AsiaJAMA, 2009
- Trends in the globalization of clinical trialsNature Reviews Drug Discovery, 2008